Anthony Recupero Sells 3,677 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN) insider Anthony Recupero sold 3,677 shares of the firm’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $19.62, for a total value of $72,142.74. Following the transaction, the insider owned 264,467 shares of the company’s stock, valued at $5,188,842.54. This trade represents a 1.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

SiBone Trading Up 4.9%

NASDAQ:SIBN opened at $21.40 on Thursday. SiBone has a 52 week low of $12.49 and a 52 week high of $21.49. The company has a debt-to-equity ratio of 0.21, a quick ratio of 6.62 and a current ratio of 7.97. The firm’s fifty day moving average is $18.71 and its 200-day moving average is $17.07. The firm has a market cap of $928.55 million, a P/E ratio of -41.96 and a beta of 0.69.

SiBone (NASDAQ:SIBN) last released its earnings results on Monday, November 10th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.05. The business had revenue of $48.66 million for the quarter, compared to analyst estimates of $46.67 million. SiBone had a negative net margin of 11.24% and a negative return on equity of 12.86%. Equities analysts expect that SiBone will post -0.78 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Canaccord Genuity Group lifted their target price on SiBone from $26.00 to $27.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Needham & Company LLC increased their price target on SiBone from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SiBone in a research report on Monday, December 29th. Truist Financial boosted their target price on shares of SiBone from $21.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Finally, Morgan Stanley increased their target price on shares of SiBone from $20.00 to $23.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, SiBone has an average rating of “Moderate Buy” and a consensus target price of $25.00.

Hedge Funds Weigh In On SiBone

A number of institutional investors have recently modified their holdings of SIBN. Tudor Investment Corp ET AL grew its position in SiBone by 0.8% in the 3rd quarter. Tudor Investment Corp ET AL now owns 258,032 shares of the company’s stock valued at $3,798,000 after purchasing an additional 1,968 shares during the period. PharVision Advisers LLC acquired a new position in SiBone during the third quarter worth $431,000. XTX Topco Ltd lifted its stake in shares of SiBone by 70.9% in the third quarter. XTX Topco Ltd now owns 33,870 shares of the company’s stock valued at $499,000 after buying an additional 14,053 shares in the last quarter. Virtus Advisers LLC lifted its stake in shares of SiBone by 174.3% in the third quarter. Virtus Advisers LLC now owns 11,333 shares of the company’s stock valued at $167,000 after buying an additional 7,201 shares in the last quarter. Finally, Quarry LP grew its holdings in shares of SiBone by 862.6% during the third quarter. Quarry LP now owns 4,861 shares of the company’s stock valued at $72,000 after buying an additional 4,356 shares during the last quarter. 98.11% of the stock is owned by institutional investors and hedge funds.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.